Objective-Cord blood-derived human endothelial colony-forming cells (ECFCs) bear a high proliferative capacity and potently enhance tissue neovascularization in vivo. Here, we investigated whether the leading mechanism for the functional improvement relates to their physical vascular incorporation or perivascular paracrine effects and whether the effects can be further enhanced by dual-cell-based therapy, including mesenchymal stem cells (MSCs). Methods and Results-ECFCs or MSCs were lentivirally transduced with thymidine kinase suicide gene driven by the endothelial-specific vascular endothelial growth factor 2 (kinase insert domain receptor) promoter and evaluated in a hindlimb ischemia model. ECFCs and MSCs enhanced neovascularization after ischemic events to a similar extent. Dual therapy using ECFCs and MSCs further enhanced neovascularization. Mechanistically, 3 weeks after induction of ischemia followed by cell therapy, ganciclovir-mediated elimination of kinase insert domain receptor ϩ cells completely reversed the therapeutic effect of ECFCs but not that of MSCs. Histological analysis revealed that ganciclovir effectively eliminated ECFCs incorporated into the vasculature. Conclusion-Endothelial-specific suicide gene technology demonstrates distinct mechanisms for ECFCs and MSCs, with complete abolishment of ECFC-mediated effects, whereas MSC-mediated effects remained unaffected. These data strengthen the notion that a dual-cell-based therapy represents a promising approach for vascular regeneration of ischemic tissue. (Arterioscler Thromb Vasc Biol. 2012;32:e13-e21.)
D
iseases of the cardiovascular system remain the leading causes of mortality and still account for more deaths than cancer, chronic lower respiratory diseases, and accidents together. 1 Regenerative medicine using stem and progenitor cells from different sources is a rapidly growing area of research aiming for repair or replacement of injured tissues. Some previous cell-based therapies using adult-derived stem and progenitor cells showed significant, albeit modest functional improvements and, therefore, did not fulfill high expectations. 2 On the other hand, ethical controversy and immunologic barriers over pluripotent embryonic stem cells hindered their therapeutic application, whereas induced pluripotent cells are still in their infancy and require comprehensive characterization and complete depletion of teratogenic cells before their clinical use. Still, the future use of induced pluripotent cell-derived, patientspecific, highly proliferative ECFCs raises the question of potential security measures, such as the use of suicide genes to stop excessive proliferation.
To date, cell therapy based on the use of autologous endothelial progenitor cells (EPCs) still remains a safe, promising, and innovative therapeutic approach. These cells are capable of enhancing neovascularization after ischemic insults, including limb ischemia, acute myocardial infarction, and cerebral ischemia. 3 Major limitations of patient-derived EPCs from peripheral blood represent their low number, modest proliferative and migratory capacity, and limited functional in vivo activity. 4 Several approaches have been investigated to further enhance the effects of adult cell therapy, among these the combination of different cell sources 5, 6 and stimulation through various growth factors. 7 Optimization of cell therapy can be achieved only by a comprehensive understanding of the underlying mechanisms contributing to neovascularization. Although basic principles of cell therapy in cardiovascular disease have been demonstrated, 8, 9 further insights regarding the relevance of the underlying mechanisms are still needed.
Early endothelial progenitor cells have been shown to participate in ischemia-induced neovascularization via direct differentiation into endothelial as well as pericytic cells 10 -12 and stimulation of host stem cells through delivery of paracrine factors, such as vascular endothelial growth factor. 13 In the present study, we used endothelial colony-forming cells (ECFCs) as a subset of endothelial progenitor cells with reportedly strong vasculogenic potential 14 and mechanistically studied their contribution to neovascularization. For this purpose, we used the ganciclovir (GCV)-inducible herpes simplex 1 thymidine kinase (TK) suicide gene driven by the kinase insert domain receptor (KDR, or vascular endothelial growth factor receptor 2) promoter and linked to green fluorescent protein (GFP) as a reporter gene. Using this system, all endothelial-committed KDR ϩ cells can be tracked and, by administration of GCV, selectively eliminated. Moreover, we studied the salutary effects of single-versus dual-cell therapy using a distinct second cell type, namely mesenchymal stem cells (MSCs), alone or in combination with ECFCs, applying the same KDR promoter-based suicide gene approach.
Methods

Human ECFCs
ECFCs were derived from umbilical cord blood or adult peripheral blood and isolated as described previously. 15 
Human MSCs
MSCs overexpressing human telomerase reverse transcriptase for their unlimited cell growth have been characterized previously and have also been named SCP1. 16 
Cloning of GFP-KDR-TK Into the Lentiviral Vector
KDR-TK cDNA was subcloned in pLenti6/V5-DEST plasmid (Invitrogen, Darmstadt, Germany) by sticky SalI/XhoI ligation. Next, the cytomegalovirus-enhanced GFP cDNA from pLenti6-IKK-cytomegalovirus-enhanced GFP-opA plasmid was inserted into the pLenti6-KDR-TK plasmid by blunt end ligation, obtaining the pLenti6-GFP-KDR-TK plasmid.
Transduction Efficacy for ECFCs and MSCs Using GFP-KDR-TK
Successfully transduced ECFCs were selected with 10 g/mL blasticidin (Invitrogen) for 10 days. Transduction efficacy was assessed by means of GFP expression using flow cytometry. Functional activity of TK was assessed using a cell proliferation assay following GCV treatment for 6 hours (MTS assay; Promega, Madison, WI).
Hindlimb Ischemia Model
A severe model of hindlimb ischemia was performed as previously described. 7 
Assessment of Perfusion via Magnetic Resonance Perfusion Imaging
Magnetic resonance imaging experiments were performed on a clinical 3-Tesla whole-body magnetic resonance imaging system (Magnetom Verio, Siemens, Erlangen, Germany). Mice were examined using T1, T2, and time-resolved angiography with interleaved stochastic trajectories sequences. Magnetic resonance imaging perfusion data were analyzed using the perfusion software PMI 0.3. 17
Immunohistochemistry
Injected human cells were identified by double staining for human leukocyte antigen (Alexa Fluor 647-labeled, Biolegend, San Diego, CA) and lectin from Bandeiraea simplicifolia (fluorescein isothiocyanate labeled, Vector Laboratories, Burlingame, CA). Nuclei were stained with DAPI (Invitrogen), and images were analyzed using scanning confocal microscopy (Leica SP2).
For more information please see the Supplemental Materials and Methods, available online at http://atvb.ahajournals.org.
Results
Phenotyping of MSCs and ECFCs by Flow Cytometry
ECFCs strongly express the endothelial surface marker CD31 (92.2Ϯ2.8%), as well as KDR (96.2Ϯ0.1%), with the latter being a prerequisite for mediating the proangiogenic effects of vascular endothelial growth factor. Expression of the hematopoietic progenitor/endothelial cell marker CD34 was relatively strong in ECFCs (37.2Ϯ3.9%) ( Figure 1A and 1B). MSCs did not express endothelial markers such as CD31, CD34, and KDR ( Figure 1B) . Although CD31 expression in ECFCs remained stable during in vitro expansion, CD34 decreased during passaging of the cells. When ECFCs were constantly passaged at 80% confluence, the fraction of CD34 ϩ cells declined from 49.7% at passage 2 to 3.8% at passage 8, whereas expression of CD31 remained stable ( Figure 1C ). Therefore, we focused on the use of the first 3 passages for in vivo experiments.
ECFCs Show a High Proliferative Capacity In Vitro
To demonstrate the high and long-standing proliferative capacity of ECFCs, cells were kept in culture until senescence and their cell numbers were recorded and compared with peripheral blood ECFCs. Cells were regularly passaged at 80% confluence. ECFCs showed a significantly longer proliferative activity (PϽ0.05) and also a significantly higher population number (PϽ0.05) after 30 days of culturing (Figure 2A and 2B) . After confirming the typical cobblestone appearance of ECFCs (Figure 2C) , cell divisions were recorded by time-lapse microscopy to visually demonstrate the high proliferative capacities of ECFCs (Supplemental Video I).
In Vivo Neovascularization Capacity of ECFCs and MSCs
To assess the in vivo potential of these cells for vascular regeneration, we used a murine model of hindlimb ischemia. First, we studied the tissue distribution of infused ECFCs and MSCs over time. Although both cell types temporarily got trapped in the lung, ECFCs rapidly relocated to the ischemic hindlimb within 6 hours after injection ( Figure 3A and 3C ). In contrast, MSCs remained in the lung for an extended period of time, with completed relocation to the ischemic hindlimb after 24 hours following intravenous injection ( Figure 3B ). Immediately after induction of hindlimb ischemia, relative perfusion, assessed as laser Doppler-derived relative blood flow, had decreased to 5.7Ϯ0.8%, indicating strong induction of limb ischemia. After 14 days, relative perfusion spontaneously increased to 25.6Ϯ1.9% in the control group, whereas cell therapy using ECFCs and MSCs separately significantly enhanced recovery of relative perfusion (ECFCs 52.2Ϯ4.0%; MSCs 47.9Ϯ2.7%; both PϽ0.05 versus control). Even more importantly, combinational therapy using coinjection of ECFCs and MSCs further and significantly increased relative These data suggest that combinational therapy using 2 complementary cell types, human endothelial and mesenchymal progenitor cells, is capable of generating enhanced treatment effects and subsequently leading to significantly better recovery of limb blood flow ( Figure 3D ). Positive effects of cell therapy could also be observed by magnetic resonance perfusion imaging. In comparison to control Figure 3E ). Mechanistically, we were able to demonstrate a significant increase in smooth muscle actin-positive vessels (Supplemental Figure I ) and an enhanced proliferation rate for murine endothelial cells (Supplemental Figure II ) in mice receiving dual-cell therapy as compared with mice treated with either single-cell therapy. Moreover, we observed a strong increase in the expression of angiogenic factors in MSCs that were exposed to ECFC-conditioned medium in vitro (Supplemental Figure III) .
Lentiviral Transduction of ECFCs and MSCs With pGFP-KDR-TK
To obtain further mechanistic insights on how ECFCs and MSCs, separately, enhance blood flow, we lentivirally transduced the cells with a plasmid containing GFP and the suicidal gene herpes simplex virus TK. GFP expression was regulated by a cytomegalovirus promoter, whereas expression of TK was controlled by the endothelial promoter KDR to allow for the specific elimination of all cells with an endothelial phenotype ( Figure 4A ). To facilitate a thorough analysis of functional mechanisms, high efficiency of transduction was mandatory. By means of resistance to blasticidin (10 g/mL) and single GFP-transgenic cell picking, we were able to reach a purity of Ͼ99% for GFP in transduced ECFCs and MSCs, whereas KDR positivity for ECFCs was sustained ( Figure 4B and 4C) . To reach 100% purity of the in vivo administered cells, ECFCs and MSCs, separately, were sorted by fluorescence-activated cell sorting before injection, ensuring that indeed all cells with an endothelial phenotype could be eliminated by the suicide gene approach. Because the suicide gene TK is expressed under the control of the endothelial promoter KDR, only transduced cells expressing KDR would be eliminated in the presence of GCV as TK phosphorylates the nontoxic prodrug GCV. Endogenous kinases can then phosphorylate GCV-monophosphate to GCVtriphosphate resulting in DNA chain termination and singlestrand breaks and subsequently induction of apoptosis. Indeed, when we measured induction of cell death using MTS assays, Twenty-four hours after induction of hindlimb ischemia zsGreen-transduced ECFCs (given in red) were intravenously injected. At the indicated time points, mice were euthanized, and fluorescence of explanted lungs and ischemic hindlimbs was analyzed by an in vivo imaging system. Quantitation is given below the images. B, Kinetics of tissue distribution of circulating MSCs after intravenous injection using the identical techniques. C, Histological quantification of homed and incorporated ECFCs in hindlimb muscles at 6 and 24 hours. D, Relative perfusion was measured directly after induction of hindlimb ischemia (post-op; nϭ9) and 14 days following treatment with PBS (nϭ10), ECFCs (nϭ12), or MSCs (nϭ10) or combined treatment with ECFCs and MSCs (nϭ8). E, Representative magnetic resonance angiography images of PBS-, ECFC-, and MSC-treated mice 14 days after induction of hindlimb ischemia. White arrows indicate ischemic leg. In the color code, red indicates a high amount of detected contrast agent, and black indicates a low amount of detected contrast agent. Average maximum signal enhancement (SE) is provided as the difference between right and left thighs.
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ECFCs but Not MSCs Contribute to Neovascularization by Vascular Incorporation
Next, we investigated whether and to what extent the 2 different progenitor cell types contribute to neovascularization by vascular incorporation. We injected intravenously either ECFC-GFP-KDR-TK or MSC-GFP-KDR-TK 24 hours after surgical induction of hindlimb ischemia. Relative limb perfusion was assessed by laser Doppler analysis using the O2C device on day 14 to demonstrate treatment response, followed by 7 days of intraperitoneal injections of either GCV or PBS, and another round of perfusion measurements on day 21. Measurement on day 14 confirmed a similar neovascularization-promoting effect for transduced ECFCs and MSCs, as shown in Figure 3D . Intriguingly, a significant drop in limb perfusion following infusion of GCV was detected only in animals treated with transduced ECFCs (ECFC-PBS 59Ϯ2.1% versus ECFC-GCV 35.4Ϯ5.2%; PϽ0.05). The resulting perfusion levels in mice treated with ECFC-GCV were similar to the relative perfusion level of untreated control mice on day 21 (control-PBS 31.4Ϯ4.4%; control-GCV 27.9Ϯ3.3%) ( Figure 5A ).
In contrast, treatment of mice that received transduced MSCs did not display any change in perfusion levels (MSC-PBS 60.4Ϯ2.9% versus MSC-GCV 63.6Ϯ3.2%). As further evidence for significant reduction of limb perfusion following elimination of ECFCs, laser Doppler imaging was used providing consistent data with the laser Doppler analysis obtained with the O2C device ( Figure 5B ). Next, we applied the same suicide approach to dual-cell therapy in vivo using either ECFC-GFP-KDR-TK along with nontransduced MSCs or vice versa. Indeed, the enhanced neovascularization achieved by dual-cell therapy was significantly attenuated following administration of GCV when ECFC-GFP-KDR-TK and nontransduced MSCs were used ( Figure 5C and 5D ). In contrast, for MSC-GFP-KDR-TK and nontransduced ECFCs, administration of GCV did not alter perfusion levels. These results demonstrate that GCV specifically eliminated ECFC-GFP-KDR-TK, whereas KDR-TKtransduced MSCs were not affected and therefore did not substantially differentiate into KDR ϩ endothelial progeny. Therefore, MSCs must have been contributed differently, most likely by pericytic integration or paracrine mechanisms. Indeed, histological evaluation of the harvested tissue revealed high numbers of human ECFCs per mm 2 (6.6Ϯ0.8) as indicated by human-specific HLA class I ( Figure 6A-6C) . Infused ECFCs had mainly incorporated into the vessel network. Specifically, on day 21 in the absence of GCV, 89.3Ϯ4.8% of myofibers in the ischemic muscles were surrounded by vessels containing ECFCs, and 27.4Ϯ2.1% of total endothelial cells in the ischemic muscle were of ECFC origin. In mice treated with GCV for 7 days, only a very few cells per mm 2 had survived (0.67Ϯ0.3) and were rarely incorporated (0.44Ϯ0.17% of endothelial cells were of ECFC origin) ( Figure 6A-6C) .
Discussion
In the present study, using a KDR promoter linked to a TK suicide gene approach and histological analysis by confocal laser scanning microscopy, we mechanistically explored the effect of suicide gene-mediated disruption of ECFC progenitor cell therapy. We demonstrated that the effects of ECFC-based progenitor cell therapy in the setting of ischemic injury are mediated by direct vascular incorporation of KDR ϩ endothelial progenitor cells. Our in vivo data demonstrate functional impairment of relative perfusion in the ischemic limb after GCV-induced killing of KDR ϩ ECFCs as assessed by 4 different methods including laser Doppler imaging, O2C laser Doppler assessment, in vivo fluorescence imaging, and magnetic resonance angiography. In the present study, we used ECFCs (also termed late EPCs) as a late outgrowing subset of early EPCs. Rehman et al 18 showed that early EPCs strongly express the monocyte marker CD14, as well as the leukocyte marker CD45, suggesting that these cells still bear a monocyte/macrophage phenotype. This could be related to the still strong heterogeneity of the cultured cells at the early time point of harvesting, insufficient endothelial commitment of the cells, or contamination with proinflammatory cells. Stimulated by ongoing discussions about the true identity of heterogeneous EPCs, Ingram et al 19 recently identified a distinct subpopulation of endothelial progenitor cells using a clonogenic assay as a functionally advanced isolation process. These cells were named ECFCs, were shown to contain clonally expanded cells, and are capable of undergoing multiple population doublings without senescence. 20 Moreover, in contrast to these newly identified ECFCs, regular EPCs reproducibly failed to form functional vascular networks in collagen plugs. 15 Therefore, instead of using peripheral blood-derived early EPCs, we used cord blood-derived ECFCs for the present study. Alternatively, for autologous cell therapy it is conceivable to use optimized patient-derived cells before their administration, as we have recently shown that ECFCs isolated from patients with diabetes can be functionally rescued by pretreatment with globular adiponectin (gAcrp). 21 Cord blood-derived ECFCs have previously been reported to enhance neovascularization using in vivo hindlimb ischemia models. 7, [22] [23] [24] However, the underlying mechanisms have remained elusive to date. Therefore, we set out to selectively eliminate ECFCs 2 weeks after infusion into a hindlimb ischemia model to assess whether selective killing of KDR ϩ ECFCs would lead to disruption of a newly created vascular network and subsequent decline in limb perfusion. This would be indicative of physical incorporation of the cells. Lack of measurable decline of limb perfusion following GCV treatment would be most consistent with temporary paracrine modes of action, namely secretion of proangiogenic factors. In addition, alone or as dual therapy along with ECFCs, we used KDR Ϫ MSCs. GCV-induced abolishment of limb perfusion would indicate differentiation of KDR Ϫ MSCs into KDR ϩ cells incorporating into the host vasculature, whereas lack of decline in limb perfusion suggests temporary paracrine effects. Most likely these paracrine effects are required only in the early stages of the neovascularization process. 25 Although several authors have proposed paracrine effects as the most important mechanism for augmentation of neovascularization, 26 others have shown that physical incorporation plays a major role in the setting of EPC-based cell therapy using a ubiquitous promoter. 8 Indeed, the ongoing controversy regarding the mechanisms of action for EPCs may again be related to the rather vague characteristics of early EPCs, as well as the still missing definition of the true stem/ progenitor cell responsible for improved neovascularization. [27] [28] [29] Here, our data for homogeneous, highly proliferative, and endothelial-committed ECFCs using an endothelial-specific KDR promoter further corroborate the impact of physical incorporation as the driving mode of action for vascular cell therapy. Calculating the total number of ECFCs captured in the upper hindlimb reveals that approximately one third of the injected ECFCs can be found in the upper limb muscle within 24 hours of cell infusion. This high recruitment rate and the virtually complete abrogation of the ECFC-mediated therapeutic effect by a KDR-driven suicide gene approach provide compelling evidence for the functional incorporation of ECFCs into the vascular system. However, it remains surprising that a relatively small number of cells is actually capable of generating such a strong therapeutic effect, even when taking into account that the homed ECFCs will further expand during the subsequent days and weeks.
To show the mechanism of angiogenesis in bone marrow cell therapy, Yoon et al 30 used the suicide model TK linked to endothelial-, smooth muscle-, or cardiac-specific promoters and demonstrated that predominant differentiation into both endothelial and smooth muscle cells contributed to improved cardiac function after induction of myocardial infarction. Although in this study intracellular endothelial nitric oxide synthase was used as an endothelial-specific promoter, the TK suicide gene in our system was driven by the endothelial cell surface marker KDR (vascular endothelial growth factor receptor 2) promoter. Whereas the study of Yoon et al investigated differentiation of a heterogeneous pool of bone marrow cell into endothelial cells, we analyzed the perfusion-enhancing mechanism of a pure population of endothelial-committed ECFCs. Because we and others 14 had already demonstrated that ECFCs represent a potent and homogeneous cell population most suitable for stem cell-based therapy, we decided to examine the contribution of ECFCs to improve perfusion in the setting of tissue ischemia and could clearly exhibit their functional incorporation as endothelial cells.
For the present study, we also used well-characterized MSCs 16 as a distinct cell source for regeneration of ischemic tissue. These cells were picked from individual single clones and overexpress telomerase, therefore composing a stable, homogeneous, and fast growing population most suitable for mechanistic studies. 16 As isolation of MSCs from the bone marrow can be a rather painful procedure, bears infectious risks for the patient, and usually gives rise to only a small percentage of MSCs known to proliferate rather slowly, this alternative and unlimited source of MSCs may indeed prove useful for clinical applications, which usually require large numbers of cells. Certainly this would require further preclinical tests to exclude safety risks related to overexpression of telomerase. 31 MSCs have been reported to differentiate in vitro into various cell types, including chondrocytes, adipocytes, and osteoblasts, 32 but there is also increasing evidence that these cells also harbor proangiogenic potential. 33 Indeed, a first phase 1 trial using allogeneic adult human MSCs after acute myocardial infarction has recently been initiated. 34 Although this clinical study was rather designed to assess feasibility and safety, MSC-based cell therapy has already been shown to be superior to placebo treatment. Although some investigators have described paracrine effects as the driving mechanism for the observed improvements in tissue perfusion, [35] [36] [37] others observed pericytic engraftment as an essential mechanism. 6, 38 Interestingly, Melero-Martin et al 6 reported that in a Matrigel plug model, MSCs differentiated into smooth muscle cells only after coimplantation with endothelial progenitor cells, whereas neither MSCs nor endothelial progenitor cells alone were able to adopt a smooth muscle cell phenotype. These data suggest that ECFC-based cell therapy might also profit from simultaneous MSC administration by smooth muscle cell-enhanced vascular stability. Using ECFCs and MSCs in our study, we could clearly demonstrate that these distinct cell types were able to enhance neovascularization individually, but their combined use resulted in further enhanced recovery of blood flow. Studying the expression of putative paracrine factors in MSCs exposed to ECFC-conditioned medium, we observed upregulation of a wide range of cytokines involved in tissue neovascularization. Based on our previous results demonstrating a concerted action of a diverse set of cytokines in the process of homing and vascular incorporation of ECFCs, this reciprocal activation of the 2 cell populations could represent an important mechanism for enhancing response to cell-based therapy. 7 Although future studies will need to further dissect this intricate interplay of MSCs and ECFCs in vivo by the use of independently inducible suicide genes in ECFCs and MSCs, we here were able to demonstrate distinct mechanisms for ECFCs and MSCs with complete abolishment of ECFCmediated effects, whereas MSC-mediated effects remained unaffected. These data strengthen the notion that a dual-cell-based therapy represents a promising approach for vascular regeneration of ischemic tissue to improve the clinical course of patients with cardiovascular diseases.
